EP0491897A1 - Liquid oral pharmaceutical compositions having anti-inflammatory activity - Google Patents
Liquid oral pharmaceutical compositions having anti-inflammatory activityInfo
- Publication number
- EP0491897A1 EP0491897A1 EP91911791A EP91911791A EP0491897A1 EP 0491897 A1 EP0491897 A1 EP 0491897A1 EP 91911791 A EP91911791 A EP 91911791A EP 91911791 A EP91911791 A EP 91911791A EP 0491897 A1 EP0491897 A1 EP 0491897A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions according
- active ingredient
- ketoprofen
- cyclodextrins
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 6
- 239000008203 oral pharmaceutical composition Substances 0.000 title description 2
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 6
- 230000000699 topical effect Effects 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 229960000991 ketoprofen Drugs 0.000 claims description 15
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical group OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 15
- 229920000858 Cyclodextrin Polymers 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000000227 bioadhesive Substances 0.000 claims description 7
- 229960001680 ibuprofen Drugs 0.000 claims description 7
- -1 methyl isosorbide Chemical compound 0.000 claims description 7
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 5
- 229940097362 cyclodextrins Drugs 0.000 claims description 5
- 229960002702 piroxicam Drugs 0.000 claims description 5
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 3
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- IHHXIUAEPKVVII-ZSCHJXSPSA-N [(1s)-5-amino-1-carboxypentyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCC[NH3+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 IHHXIUAEPKVVII-ZSCHJXSPSA-N 0.000 claims description 2
- 229960004892 acemetacin Drugs 0.000 claims description 2
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 229960004492 suprofen Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 229960005142 alclofenac Drugs 0.000 claims 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960002479 isosorbide Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 11
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 11
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 11
- 235000010234 sodium benzoate Nutrition 0.000 description 11
- 239000004299 sodium benzoate Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 10
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 10
- 229920001214 Polysorbate 60 Polymers 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 8
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 8
- 239000000600 sorbitol Substances 0.000 description 8
- 235000010356 sorbitol Nutrition 0.000 description 8
- 229960002920 sorbitol Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 5
- 239000003708 ampul Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229960000333 benzydamine Drugs 0.000 description 4
- 239000001116 FEMA 4028 Substances 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229940044519 poloxamer 188 Drugs 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- SSVFMICWXDVRQN-UHFFFAOYSA-N ethanol;sodium Chemical compound [Na].CCO SSVFMICWXDVRQN-UHFFFAOYSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Definitions
- the present invention relates to liquid pharmaceu ⁇ tical compositions for the oral topical treatment, containing non steroidal anti-inflammatory drugs as the active ingredients.
- Therapeutical treatment of inflammations of the oral cavity such as aspecific odontostomatologic af ⁇ fections, gingivitis, glossitis, stomatitis and the like, is particularly complex and, until the specific pathogenic agent has precisely been determined, treat- ment can be restricted to the use of disinfectants of the general type.
- Said drugs besides showing negative characteri ⁇ stics (remarkable side-effects) can cause severe and diffused allergy phenomena, so as to compel to immedia- tely interrupt treatment and to take suitable restora ⁇ tion measures.
- compositions comprising non steroidal anti-inflammatory drugs (FANS) in form of solutions intended for the oral topical tre ⁇ atment (collutories) , allow to obtain very good thera ⁇ Promotionical results without causing sensitization pheno ⁇ mena.
- FANS non steroidal anti-inflammatory drugs
- the compositions of the invention are characteri ⁇ zed by the presence of a specific excipient, dimethyl isosorbide, giving them advantageous antiseptic proper ⁇ ties together with an antiplaque action which is parti- cularly desired in this kind of preparations.
- Anti-in ⁇ flammatory properties of the active ingredients also turn out to be surprisingly enhanced through a synerge- tic interaction with dimethyl isosorbide.
- compositions of the present invention can con- tain the active ingredient in amounts ranging from 0.001 to 20% by weight, whereas dimethyl isosorbide can be present in amounts ranging from 1 to 40% by weight.
- compositions of the invention can also contain other excipients and/or coadjuvants, such as surfactants, flavouring and sweetening agents, in order to give the preparation suitable organoleptic characteristics.
- excipients and/or co ⁇ adjuvants conventionally used for the preparation of collutories are described in "Remington's Pharm. Scien- ces Handbook", Mack Pub. Co., NY.
- the compositions of the invention will preferably contain natural and/or synthetic sweetening agents such as saccharine, ammo ⁇ nium glycyrrhizinate, cycla ate or, more preferably, not cariogenic carbohydrates such as xylitol and sorbi- tol.
- non steroidal anti- inflammatory drugs such as ketoprofen, ibuprofen, ibu- profen lysine salt, naproxen, suprofen, diclofenac, al- clofenac, indomethacin, acemethacin, benzidamine, flur- biprofen, piroxicam and the like, can be used as active ingredients, either in the free form or salified, in order to improve the solubility thereof.
- the active ingredients are present in combination with cyclodextrins or derivatives thereof, for example in form of physical admixtures, inclusion products or co- precipitates.
- Cyclodextrins or derivatives thereof such as hydroxypropyl beta-cyclodextrins, involve fa ⁇ vourable pharmacokinetic effects and, moreover, are useful to increase solubility and stability, or to im- prove the organoleptic characteristics of the medica ⁇ ment.
- Cyclodextrin contents can range from 0.5 to 50% by weight of the finished composition, but equimolecular ratios of active ingredient to cyclodextrin are prefe- rably used.
- cyclodex ⁇ trins (o , ⁇ , -) and the already cited hydroxypropyl ⁇ - cyclodextri ⁇ , dimethylcyclodextrins or other derivati ⁇ ves, possibly in a mixture thereof can also be used.
- polymers having an adhesive power towards ucosae are used as excipients.
- examples of said polymers are provided by carboxyvinyl polymers, ethyle e oxide - propylene oxide copolymers, cellulose derivatives such as carboxymethyl cellulose, calcium carboxymethyl cellulose, hydroxy- propylethyl cellulose, hydroxyethyl cellulose, hydroxy ⁇ propyl cellulose, carrageenan, dextrins, natural or synthetic gums and the like.
- Said excipients, which can be def ned bioadhesive polymers can be present in per ⁇ centages ranging from 0.5 to 30%, preferably from 1 to 5%.
- excipients allows to obtain sli ⁇ ghtly viscous solutions having adhesiveness towards mu- cosae, so as to achieve a better persistence of the preparation in contact with the area to be treated, thus obtaining a more effective and lasting action.
- compositions can also contain no dimethyl isosor- bide : said compositions also fall within the scope of the present invention.
- Each 15 ml ampoule contains: Active ingredient: ketoprofen Excipients:
- Ketoprofen is dissolved in an ethanol solution containing dimethyl isosorbide and Tween 60, the solu ⁇ tion is heated to 35 C C under stirring, to obtain a clear solution which is added with the other components. After filtration, a clear homogeneous solution (collutory) is obtained.
- Ketoprofen is added to a ⁇ -cyclodextrin aqueous solution (about 50 ml), which is heated to 30-40 e C for 30 hours. A solution is obtained which is added with dimethyl isosorbide and the other components, then fil ⁇ tered.
- EXAMPLE 4 Collutory containing ketoprofen, dimethyl isosorbide and bioadhesive polymers (in form of solution) 100 ml of collutory contain (% composition): Active ingredient: ketoprofen 0.05 Excipients:
- Each 15 ml ampoule contains : Active ingredient: Benzidamine 2 to 20 mg ExciDients: Tween 60 5 mg alpine herb flavor 52,503 T 15 mg dimethyl isosorbide 1500 mg
- Collutory containing piroxicam (in form of solution) 100 ml of collutory contain (% composition) : Active ingredient:
- Each 15 ml ampoule contains: Active ingredient: Piroxicam Excipients:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT02094490A IT1243342B (it) | 1990-07-13 | 1990-07-13 | Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria |
| IT2094490 | 1990-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0491897A1 true EP0491897A1 (en) | 1992-07-01 |
Family
ID=11174427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP91911791A Withdrawn EP0491897A1 (en) | 1990-07-13 | 1991-07-04 | Liquid oral pharmaceutical compositions having anti-inflammatory activity |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0491897A1 (enrdf_load_stackoverflow) |
| AU (1) | AU8093591A (enrdf_load_stackoverflow) |
| CA (1) | CA2066731A1 (enrdf_load_stackoverflow) |
| ES (1) | ES2034926T1 (enrdf_load_stackoverflow) |
| GR (1) | GR930300021T1 (enrdf_load_stackoverflow) |
| IT (1) | IT1243342B (enrdf_load_stackoverflow) |
| WO (1) | WO1992000725A1 (enrdf_load_stackoverflow) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| JP4439590B2 (ja) * | 1992-06-10 | 2010-03-24 | エラン ファーマ インターナショナル，リミティド | 表面改質ｎｓａｉｄナノ粒子 |
| WO1994013280A1 (en) * | 1992-12-04 | 1994-06-23 | Mayor Pharmaceutical Laboratories, Inc. | Sprayable analgesic composition and method of use |
| PT701449E (pt) * | 1993-06-08 | 2003-12-31 | Novartis Ag | Processo de preparacao de uma forma de dosagem solida oral contendo diclofenac |
| KR100304064B1 (ko) * | 1993-08-12 | 2001-11-22 | 다카하시 미치나오 | 구강용조성물 |
| GB9318880D0 (en) * | 1993-09-11 | 1993-10-27 | Smithkline Beecham Plc | Pharmaceutical composition |
| IL111184A (en) * | 1993-10-08 | 2000-08-13 | Farmarc Nederland B V Of Cito | Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin |
| ZA949182B (en) * | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
| US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
| EP0839029A1 (en) * | 1995-07-20 | 1998-05-06 | PHARMACIA & UPJOHN COMPANY | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| HUP9600758A2 (en) * | 1996-03-27 | 1998-03-02 | Cyclolab Ciklodextrin Kutato F | Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption |
| DE19651055B4 (de) * | 1996-12-09 | 2006-03-16 | Beiersdorf Ag | Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Dimethylisosorbid und deren Verwendung |
| GB9710521D0 (en) | 1997-05-22 | 1997-07-16 | Boots Co Plc | Process |
| ES2171110B1 (es) * | 2000-03-03 | 2003-06-16 | Aplicaciones Farmacodinamicas | Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion. |
| ITMI20020986A1 (it) * | 2002-05-10 | 2003-11-10 | Acraf | Composizione a base di diclofenac per il trattamento topico di affezioni del cavo orofaringeo |
| ZA200508653B (en) * | 2003-04-07 | 2007-03-28 | Jurox Pty Ltd | Stable carprofen composition |
| FR2865648B1 (fr) | 2004-02-03 | 2006-06-30 | Philippe Perovitch | Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede |
| CA2647348A1 (en) | 2006-03-28 | 2007-10-04 | Javelin Pharmaceuticals, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
| CN102448499A (zh) * | 2009-04-27 | 2012-05-09 | 药效学应用实验室股份有限公司 | 赖氨酸布洛芬口服混悬剂 |
| ES2347754B8 (es) * | 2009-04-27 | 2012-06-04 | Laboratorio De Aplicaciones Farmacodinamicas, S.A | Suspension oral de lisinato de ibuprofeno |
| GB201021267D0 (en) * | 2010-12-15 | 2011-01-26 | Reckitt Benckiser Healthcare Int Ltd | Novel pharmaceutical formulation |
| JP2021504306A (ja) * | 2017-11-30 | 2021-02-15 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | ケトプロフェン、その塩およびエナンチオマーの安定な液体組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3532562A1 (de) * | 1985-09-12 | 1987-03-12 | Dolorgiet Gmbh & Co Kg | Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben |
| BE1000381A4 (fr) * | 1987-03-13 | 1988-11-16 | Pharlyse Sa | Preparation pharmaceutique a base d'indometacine. |
| IT1223343B (it) * | 1987-11-03 | 1990-09-19 | Also Lab Sas | Formulazioni farmaceutiche per somministrazione transdermica |
-
1990
- 1990-07-13 IT IT02094490A patent/IT1243342B/it active IP Right Grant
-
1991
- 1991-07-04 EP EP91911791A patent/EP0491897A1/en not_active Withdrawn
- 1991-07-04 ES ES199191911791T patent/ES2034926T1/es active Pending
- 1991-07-04 CA CA002066731A patent/CA2066731A1/en not_active Abandoned
- 1991-07-04 AU AU80935/91A patent/AU8093591A/en not_active Abandoned
- 1991-07-04 WO PCT/EP1991/001245 patent/WO1992000725A1/en not_active Application Discontinuation
-
1993
- 1993-04-28 GR GR930300021T patent/GR930300021T1/el unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9200725A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU8093591A (en) | 1992-02-04 |
| GR930300021T1 (enrdf_load_stackoverflow) | 1993-04-28 |
| CA2066731A1 (en) | 1992-01-14 |
| IT9020944A0 (it) | 1990-07-13 |
| IT9020944A1 (it) | 1992-01-13 |
| WO1992000725A1 (en) | 1992-01-23 |
| ES2034926T1 (es) | 1993-04-16 |
| IT1243342B (it) | 1994-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0491897A1 (en) | Liquid oral pharmaceutical compositions having anti-inflammatory activity | |
| EP0441307B1 (en) | Syrup composition | |
| RU2272636C2 (ru) | Фармацевтическая композиция для местного лечения воспаления и способ ее изготовления | |
| JPH05504783A (ja) | 水溶解性の高いシクロデキストリン誘導体組成物及びその用途 | |
| JP2002510652A5 (enrdf_load_stackoverflow) | ||
| EP0444492A1 (en) | Topically administered compositions based on high molecular weight hyaluronic acid for treating inflammations of the oral cavity, and for oral cavity hygiene and cosmetic treatment | |
| JPH0257049B2 (enrdf_load_stackoverflow) | ||
| WO2001041757A1 (fr) | Composition pharmaceutique contenant de la cyclodextrine | |
| EP0633787B1 (en) | Use of ibuprofen-beta-cyclodextrin complex for oral consumption | |
| HU225896B1 (en) | Topical anti-inflammatory compositions containing piroxicam | |
| JP4195178B2 (ja) | 消炎鎮痛外用剤 | |
| EP1974751A1 (en) | Formulations for non-steroidal anti-inflammatory drugs | |
| HUP0500842A2 (hu) | Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra | |
| PT1609481E (pt) | Composições farmacêuticas injectáveis compreendendo diclofenaco de sódio de beta-ciclodextrina e um polissorbato | |
| AU2003232480B2 (en) | Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders | |
| JPH0616547A (ja) | 消炎点眼剤 | |
| EP0867181A1 (en) | Nasal melatonin composition | |
| JPH035438A (ja) | フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤 | |
| CA2259270C (en) | Pharmaceutical preparation containing nimesulide for oral administration | |
| CA2486571C (en) | Pharmaceutical composition | |
| EP1242062B1 (en) | Anhydrous gel comprising nsaid for topical administration to the oral cavity | |
| KR100567131B1 (ko) | 쓴맛을 차폐한 아르기닌 함유 이부프로펜 경구투여 액상조성물 | |
| JPS59122422A (ja) | 口腔用消炎鎮痛ゲル剤 | |
| KR100509432B1 (ko) | Ｓ(+)-이부프로펜을 함유한 시럽제 조성물 및 그의 제조방법 | |
| JPS58116423A (ja) | メタノプロスタサイクリン製剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19920303 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: L.C. PHARCHEM LTD. |
|
| ITCL | It: translation for ep claims filed |
Representative=s name: STUDIO BIANCHETTI |
|
| EL | Fr: translation of claims filed | ||
| TCAT | At: translation of patent claims filed | ||
| DET | De: translation of patent claims | ||
| TCNL | Nl: translation of patent claims filed | ||
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: BA2A Ref document number: 2034926 Country of ref document: ES Kind code of ref document: T1 |
|
| 17Q | First examination report despatched |
Effective date: 19930308 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8580 Free format text: DER ANMELDER LAUTET RICHTIG: L.C. PHARCHEM LTD., NICOSIA, CY |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19941101 |